Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow Transplantation
- Conditions
- Lymphoma
- Registration Number
- NCT01891578
- Lead Sponsor
- Armando Santoro, MD
- Brief Summary
Evaluation of immunological reconstitution after haploidentical BMT using a nonmyeloablative preparative regimen and post-transplant cyclophosphamide in patients with poor prognosis lymphoma
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
- Patients with lymphoma (any histology) relapsed after high dose chemotherapy and in partial remission, complete remission or stable disease after the last CT line that
- Signed informed consent to perform an haploidentical allo-BMT using a nonmyeloablative preparative regimen and post-transplant cyclophosphamide
Exclusion Criteria
none
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of T lymphocytes and NK cells absolute number 1 year
- Secondary Outcome Measures
Name Time Method Evaluation of discrete T-cells populations 1 year Evaluation, by flow cytometry, of discrete T cell populations, including CD4+ and CD8+ TN, TSCM, TCM and TEM, NK and NKT cells, B cells, dendritic cell subsets
Evaluation of antigen-specific T cell populations 1 year Evaluation of antigen-specific T cell frequency towards CMV, EBV and influenza virus by MHC tetramers
Evaluation of antigen-specific T lymphocyte's functionality 1 year antigen-specific T lymphocyte's functionality towards tumor cell line evaluated using a degranulation assay
Evaluation of cytokines production by IL-2 and anti-CD16 activated NK cells 1 year
Trial Locations
- Locations (1)
Istituto Clinico Humanitas
🇮🇹Rozzano, MI, Italy